[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"toxoplasmosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:toxoplasmosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,61,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100619608","role-of-circulating-micrornas-in-differentiating-psychological-disorders-among-women-with-chronic-toxoplasmosis-100619608",false,"NCT07346833","Role of Circulating MicroRNAs in Differentiating Psychological Disorders Among Women With Chronic Toxoplasmosis","Deciphering The Role of Circulating MicroRNAs To Differentiate Psychological Disorders Among Women With Chronic Toxoplasmosis","Inclusion Criteria:\n\n* Confirmed psychiatric diagnosis of Schizophrenia (SCZ), Major Depressive Disorder (MDD), or Bipolar Disorder (BD) according to DSM-5 criteria.\n* Seronegative for T. gondii IgM (to ensure infection is not in the acute phase).\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Psychiatric disorders other than Schizophrenia, MDD, and Bipolar Disorder.\n\nSeropositive for T. gondii IgM (indicating acute infection).\n\nRefusal to participate.","FEMALE","18 Years","50 Years",{"count":20,"type":21},55,"ESTIMATED","OBSERVATIONAL","Chronic Toxoplasma gondii (T. gondii) infection is a widespread condition that can negatively affect brain function and is considered a risk factor for various psychiatric conditions, including depression and schizophrenia. This prospective observational study aims to investigate the expression levels of specific circulating microRNAs (miRNAs) in women diagnosed with schizophrenia, major depressive disorder, or bipolar disorder who also have chronic toxoplasmosis. By comparing these levels to patients without the infection, the study seeks to determine if these miRNAs can serve as biological markers to help differentiate between specific psychological disorders and identify the impact of chronic toxoplasmosis on mental health.",[25],"Toxoplasmosis","RECRUITING","2026-01-08",{"date":29,"type":30},"2026-01-16","ACTUAL",{"date":32,"type":30},"2025-11-20",{"date":34,"type":21},"2026-04",{"name":36,"class":37},"Benha University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":46,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":38},"100597163","isolated-positive-toxoplasma-gondii-pcr-in-blood-100597163","NCT07054918","Isolated Positive Toxoplasma Gondii PCR in Blood","TIPS","Inclusion Criteria:\n\n* T. gondii positive-PCR in blood during the study period: no symptoms of toxoplasmosis since the last systematic PCR negative in blood and no history of T. gondii positive-PCR in any biological matrix for 6 weeks.\n\nExclusion Criteria:\n\n* pre-analytical or analytical error leading to a false-positive result\n* unknown toxoplasmosis immune status or non-immune subject\n* serology in favor of acute toxoplasmosis\n* congenital toxoplasmosis, ocular toxoplasmosis, toxoplasmosis in the context of HIV\u002FAIDS\n* patient opposition","ALL",{"count":48,"type":21},100,"Toxoplasmosis in immunocompromised patients is a serious, life-threatening condition that requires rapid, appropriate treatment. Diagnosis is based on PCR, notably on blood samples. Systematic blood screening is carried out for patients most at risk, to detect the disease at an early stage. Detection of parasite DNA in blood in asymptomatic patients is possible, in the absence of Toxoplasma multiplication. It has previously been proposed a distinction of two entities: toxoplasmosis disease (clinical, biological and imaging evidence of toxoplasmosis) and toxoplasmosis infection (positive PCR in the blood in the absence of clinical or radiological evidence, without progression to toxoplasmosis). Since the clinical signs of toxoplasmosis are often aspecific, a positive PCR may be the first warning result, making it difficult to determine whether the patient will progress to toxoplasmosis disease or toxoplasmosis infection.\n\nIn collaboration with the French National Reference Center for toxoplasmosis, we are proposing a retrospective multicenter study to identify possible clinical, biological or imaging criteria pointing to toxoplasmosis disease or toxoplasmosis infection as soon as the first T. gondii PCR result is positive in the blood.",[25],"NOT_YET_RECRUITING","2025-07-08",{"date":54,"type":30},"2025-07-11",{"date":56,"type":21},"2025-09",{"date":58,"type":21},"2026-03",{"name":60,"class":37},"University Hospital, Clermont-Ferrand",{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":46,"minAge":17,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":72,"conditions":73,"keywords":74,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":38},"100539563","prognosis-of-disseminated-and-cerebral-toxoplasmosis-hospitalized-in-intensive-care-in-the-era-of-pcr-diagnosis-100539563","NCT06305468","Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis","Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis - Toxoplasmosis in ICU (TOXIC)","TOXIC","Inclusion Criteria:\n\n* Adult patient hospitalized in intensive care\n* At least 1 organ failure (SOFA\\> or =2)\n* PCR toxoplasmosis on CSF, blood, BAL, or bone marrow positive within 7 days before or after admission to ICU\n\nExclusion Criteria:\n\n* Post-mortem diagnosis\n* Primary outcome not available\n* Patient living informed and not opposed to the reuse of their data in this research.","100 Years",{"count":71,"type":21},200,"Toxoplasmosis is a common infection whose clinical severity can sometimes justify admission to intensive care, especially in immunocompromised patients.\n\nThis study should make it possible to evaluate the impact of different anti-infective treatment regimens and to highlight clinical-biological and prognostic differences depending on the type of underlying immunosuppression.",[25],[75],"toxoplasmosis","2025-01-24",{"date":78,"type":30},"2025-01-28",{"date":80,"type":30},"2024-08-01",{"date":82,"type":21},"2026-04-01",{"name":84,"class":37},"Assistance Publique - Hôpitaux de Paris",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":46,"minAge":4,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":38},"100056915","phase-4-pyrimethamine-sulfadiazine-and-leucovorin-in-treating-patients-with-congenital-toxoplasmosis-100056915","NCT00004317","Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis","Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis","PROTOCOL ENTRY CRITERIA:\n\n* Infants with congenital toxoplasmosis Toxoplasma gondii confirmed prior to age 2.5 months\n* Pregnant women with evidence of toxoplasma infection by clinical observation and amniotic fluid sampling\n* Acute infection acquired during gestation with evidence of fetal infection\n* Untreated older children entered as controls\n* Asymptomatic congenital toxoplasmosis\n* Age more than 1 year\n* No treatment within the first year of life\n* No more than 1 month of prior therapy",{"count":93,"type":21},600,"INTERVENTIONAL",[96],"PHASE4","RATIONALE: Congenital toxoplasmosis is an infection caused by the parasitic organism Toxoplasma gondii, and it may be passed from an infected mother to her unborn child. The mother may have mild symptoms or no symptoms; the fetus, however, may experience damage to the eyes, nervous system, skin, and ears. The newborn may have a low birth weight, enlarged liver and spleen, jaundice, anemia, petechiae, and eye damage. Giving the antiparasitic drugs pyrimethamine and sulfadiazine is standard treatment for congenital toxoplasmosis, but it is not yet known which regimen of pyrimethamine is most effective for the disease.\n\nPURPOSE: Randomized phase IV trial to determine which regimen of pyrimethamine is most effective when combined with sulfadiazine and leucovorin in treating patients who have congenital toxoplasmosis.",[25],[100,101,75],"immunologic disorders and infectious disorders","rare disease","2009-05-13",{"date":104,"type":21},"2009-05-14",{"date":106,"type":4},"2000-07",{"date":108,"type":21},"2030-12",{"name":110,"class":111},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH"]